San Diego-centered Viking Therapeutics marked alone as a serious competitor in the weight loss drug sector in February soon after revealing promising details from the mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when specified as being a weekly injection As well as in March the c